At Ajna, our science team is working to develop the world’s first FDA-approved full-spectrum cannabinoid drug and a robust pipeline of other plant medicines.
UNLOCKING NATURE IN THE LABORATORY
DRUG DEVELOPMENT PLATFORM OF THE FUTURE
Ajna HQ’s State-of-the-Art Facility & Specialized Instrumentation
Situated near Denver, Colorado, our 13,500 sq.ft. DEA Schedule 1 facility goes beyond conventional labs. We've equipped ourselves with specialized tools like Quadrupole Time of Flight Mass Spectrometry, tailor-made for characterizing complex botanical mixtures and identifying new molecules in plant extracts. This integration of cutting-edge cultivation, extraction, analytical, and 211 cGMP production capabilities uniquely positions us in the evolving landscape of botanical drug development.
Drug Development Programs
AJA001: Cannabis sativa
Full Spectrum Cannabinoid Formulation for Autism Spectrum Disorder
The ASD community urgently needs better therapeutic options. Currently, only 2 drugs are FDA-approved to address this condition, and both come with severe adverse side effects.
Through DEFLORIA LLC, a newly formed Joint Venture between Ajna, Charlotte’s Web, and BAT, we are pioneering the development of AJA001. This investigational new drug is poised to be the world's first FDA-Approved, full-spectrum botanical hemp extract specifically tailored to address the debilitating symptoms of Autism Spectrum Disorder. For more information about AJA001 and DEFLORIA see DeFloria.bio
By leveraging CW’s patented genetics and an optimized formulation designed for peak bioavailability, AJA001 has the potential to revolutionize treatment for ASD. It provides not only symptom relief, but also an enhanced quality of life, paving the way for brighter futures for both patients and families.
Phase I clinical trials are currently underway, and a Johns Hopkins open label study shows promising results.
AJA002: Psilocybe cubensis
Full Spectrum Psilocybin
Novel Anti-Depressant
U.S. Doctors prescribed over 238 million daily use anti-depressants in 2020, generating an estimated $18.8B in revenue.
Conventional anti-depressants like SSRIs don’t work for everyone, and grey market microdosing of psilocybin for depression is becoming increasingly popular.
A standardized botanical daily microdose will be in high demand, and Ajna aims to capture 6% of the daily-use anti-depression market by providing a fully characterized and FDA-approved formulation.
“Having a new class of drugs is going to be an exciting new avenue for research and could be a very important alternative to existing treatments. What’s needed is companies like Ajna to bring a pharmaceutical approach to developing these medications and doing the proper research to bring them to market.”Dr. Ryan Vandrey, Johns Hopkins University
Professor of Psychiatry and Behavioral Sciences / Director, Cannabinoid Research Unit / Ajna Scientific Board Member